OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143

Background: Patients with glioblastoma (GBM) have a 5-year survival rate of approximately 5%, indicating that novel therapeutic options are critically needed. Nivolumab, a fully human IgG4 monoclonal antibody inhibitor of the programmed death-1 receptor, has provided durable and clinically significa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Omuro, A., Vlahovic, G., Baehring, J., Butowski, N., Reardon, D., Cloughesy, T., Sahebjam, S., Lim, M., Zwirtes, R., Sampson, J.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
ORAL PRESENTATIONS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.044
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars